Immunotherapy News and Research

Latest Immunotherapy News and Research

Researchers present a new strategy for self-adjuvanting vaccine development

Researchers present a new strategy for self-adjuvanting vaccine development

Plasma GH is a biomarker candidate for predicting outcomes in advanced HCC patients treated with Atezo/Bev

Plasma GH is a biomarker candidate for predicting outcomes in advanced HCC patients treated with Atezo/Bev

Extracellular vesicles enhance cancer immunotherapy

Extracellular vesicles enhance cancer immunotherapy

Impact of epigenetics on the clinical management of cancer patients

Impact of epigenetics on the clinical management of cancer patients

CARxALL clinical trial approved to evaluate CAR-T technology for patients with T-cell leukemia subtype

CARxALL clinical trial approved to evaluate CAR-T technology for patients with T-cell leukemia subtype

ACAAI’s two new yardsticks on managing eosinophilic esophagitis and cough published

ACAAI’s two new yardsticks on managing eosinophilic esophagitis and cough published

Analysis finds more than 100 new genetic risk factors strongly linked to colorectal cancer

Analysis finds more than 100 new genetic risk factors strongly linked to colorectal cancer

CU study proves effectiveness of new multidrug treatment for patients with stage IV melanoma

CU study proves effectiveness of new multidrug treatment for patients with stage IV melanoma

Mucosal DNA vaccine provides protection against lethal SARS-CoV-2 in mice

Mucosal DNA vaccine provides protection against lethal SARS-CoV-2 in mice

Novel immunotherapy offers a promising new strategy to fight hard-to-treat cancers

Novel immunotherapy offers a promising new strategy to fight hard-to-treat cancers

Experimental therapy shows promise as treatment for metastatic colon cancer in preclinical models

Experimental therapy shows promise as treatment for metastatic colon cancer in preclinical models

Using synthetic gene cir­cuits to better control the timing of immunotherapy

Using synthetic gene cir­cuits to better control the timing of immunotherapy

Researchers discover how certain breast cancers persist after chemo and do not respond to immunotherapies

Researchers discover how certain breast cancers persist after chemo and do not respond to immunotherapies

Study identifies Δ42PD-1 as novel therapeutic target for hepatocellular carcinoma immunotherapy

Study identifies Δ42PD-1 as novel therapeutic target for hepatocellular carcinoma immunotherapy

Major treatment advance revealed for adults with newly diagnosed B lineage acute lymphoblastic leukemia

Major treatment advance revealed for adults with newly diagnosed B lineage acute lymphoblastic leukemia

Expansion of intermediate cells in prostate cancer correlates with treatment resistance and poor outcomes

Expansion of intermediate cells in prostate cancer correlates with treatment resistance and poor outcomes

Ongoing Phase I clinical trial demonstrates successful re-treatment with CAR T cell therapy

Ongoing Phase I clinical trial demonstrates successful re-treatment with CAR T cell therapy

Off-the-shelf immunotherapy could offer new hope for patients with hard-to-treat multiple myeloma

Off-the-shelf immunotherapy could offer new hope for patients with hard-to-treat multiple myeloma

A-HIPI decision model can predict survival in adults with advanced-stage Hodgkin lymphoma

A-HIPI decision model can predict survival in adults with advanced-stage Hodgkin lymphoma

Scientists develop new receptor “decoy” drug that potently neutralizes SARS-CoV-2 variants

Scientists develop new receptor “decoy” drug that potently neutralizes SARS-CoV-2 variants

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.